The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution

References

• Baldi GG, Orbach D, Bertulli R, et al. Standard treatment and emerging drugs for managing synovial sarcoma: adult’s and pediatric oncologist perspective. Expert Opin Emerg Drugs. 2019;24(1):43–53. doi:10.1080/14728214.2019.159136730841761
   PubMed Web of Science ®Google Scholar
• Riedel RF, Jones RL, Italiano A, et al. Systemic anti-cancer therapy in synovial sarcoma: a systematic review. Cancers. 2018;10:11. doi:10.3390/cancers10110417
   PubMed Web of Science ®Google Scholar
• Berry V, Basson L, Bogart E, et al. REGOSARC: regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017;123(12):2294–2302. doi:10.1002/cncr.3066128295221
   PubMed Web of Science ®Google Scholar
• Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene. 2001;20(40):5755–5762. doi:10.1038/sj.onc.120460111607825
   PubMed Web of Science ®Google Scholar
• Wang S, Song R, Sun T, et al. Survival changes in patients with Synovial Sarcoma, 19832012. J Cancer. 2017;8(10):1759–1768. doi:10.7150/jca.1734928819372
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009;115(13):2988–2998. doi:10.1002/cncr.2437019452538
   PubMed Web of Science ®Google Scholar
• Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European pediatric soft tissue sarcoma study group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2015;26(3):567–572. doi:10.1093/annonc/mdu56225488687
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Van Tine BA. Synovial Sarcoma: current concepts and future perspectives. J Clin Oncol. 2018;36(2):180–187. doi:10.1200/JCO.2017.75.194129220290
   PubMed Web of Science ®Google Scholar
• Bianchi G, Sambri A, Righi A, Dei Tos AP, Picci P, Donati D. Histology and grading are important prognostic factors in synovial sarcoma. Eur J Surg Oncol. 2017;43(9):1733–1739. doi:10.1016/j.ejso.2017.05.02028579008
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627–634. doi:10.1002/cncr.2038615274077
   PubMed Web of Science ®Google Scholar
• von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, Version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(5):536–563. doi:10.6004/jnccn.2018.002529752328
   PubMedGoogle Scholar
• Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72–83. doi:10.1016/j.ejca.2009.09.02219853437
   PubMed Web of Science ®Google Scholar
• Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 2017;18(8):1089–1103. doi:10.1016/S1470-2045(17)30381-928651927
   PubMed Web of Science ®Google Scholar
• Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, Phase 2 study. Lancet Oncol. 2015;16(4):406–416. doi:10.1016/S1470-2045(15)70098-725795406
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi:10.1016/S0140-6736(12)60651-522595799
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim HS, Lee SJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015;15:154. doi:10.1186/s12885-015-1160-x25885855
   PubMed Web of Science ®Google Scholar
• Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732–1742. doi:10.1016/S1470-2045(16)30507-127751846
   PubMed Web of Science ®Google Scholar
• Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70(20):7981–7991. doi:10.1158/0008-5472.CAN-10-011120876799
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase iii trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.599526884585
   PubMed Web of Science ®Google Scholar
• Zhu B, Li J, Xie Q, Diao L, Gai L, Yang W. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2018;19(3):198–204. doi:10.1080/15384047.2017.141627529261005
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, Version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(6):758–786. doi:10.6004/jnccn.2016.007827283169
   PubMed Web of Science ®Google Scholar
• Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133–3140. doi:10.1200/JCO.2008.20.449519451436
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–3132. doi:10.1200/JCO.2008.21.322319451427
   PubMed Web of Science ®Google Scholar
• Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–1416. doi:10.1002/cncr.2996126970174
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Judson IR, Benson C, et al. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study(). Acta Oncol. 2017;56(12):1769–1775. doi:10.1080/0284186X.2017.133277928723233
   PubMed Web of Science ®Google Scholar
• Kim JH, Park HS, Heo SJ, et al. Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue Sarcoma. Oncology. 2019;96(2):59–69. doi:10.1159/00049259730336470
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Liegl-Atzwager B, Tresch E, et al. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. BMC Cancer. 2015;15:127. doi:10.1186/s12885-015-1143-y25884155
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Mir O, Wallet J, et al. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. Eur J Cancer. 2018;99:28–36. doi:10.1016/j.ejca.2018.05.00829902612
   PubMed Web of Science ®Google Scholar
• Xie L, Guo W, Wang Y, Yan T, Ji T, Xu J. Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China. BMC Cancer. 2018;18(1):396. doi:10.1186/s12885-018-4303-z29625604
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang K, Wan X, Chen Y, Ma S, Deng Q. The use of apatinib in treating primary pleural synovial sarcoma: A case report. Medicine. 2019;98(51):e18382. doi:10.1097/MD.000000000001838231861000
   PubMed Web of Science ®Google Scholar
• Agulnik M, Attia S. Growing role of regorafenib in the treatment of patients with Sarcoma. Target Oncol. 2018;13(4):417–422. doi:10.1007/s11523-018-0575-029931504
   PubMed Web of Science ®Google Scholar
• Ranieri G, Gadaleta CD, Patruno R, et al. A model of study for human cancer: spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol. 2013;88(1):187–197. doi:10.1016/j.critrevonc.2013.03.00523561333
   PubMed Web of Science ®Google Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380. doi:10.1111/j.1349-7006.2011.01939.x21443688
   PubMed Web of Science ®Google Scholar
• van Marcke C, Ledoux B, Petit B, Seront E. Rapid and fatal acute heart failure induced by pazopanib. BMJ Case Rep. 2015;2015.
   PubMedGoogle Scholar